دورية أكاديمية
أعرض في EDS

Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis.

التفاصيل البيبلوغرافية
العنوان: Trends in management of patients with new-onset refractory status epilepticus (NORSE) from 2016 to 2023: An interim analysis.
المؤلفون: Hanin A; Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA.; Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, INSERM, CNRS, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France.; Epilepsy Unit, Department of Clinical Neurophysiology, DMU Neurosciences, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France., Jimenez AD; Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA., Gopaul M; Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA., Asbell H; Section of Neurology, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA., Aydemir S; Department of Neurology, Weill Cornell Medicine, New York City, New York, USA., Basha MM; Wayne State University School of Medicine, Detroit, Michigan, USA., Batra A; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Damien C; Department of Neurology, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium., Day GS; Washington University School of Medicine, Saint Louis, Missouri, USA., Eka O; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Eschbach K; Section of Neurology, Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA., Fatima S; Department of Neurology, University of Wisconsin, Madison, Wisconsin, USA., Fields MC; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Foreman B; Division of Neurocritical Care, Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio, USA., Gerard EE; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Gofton TE; London Health Sciences Center, University Hospital, London, Ontario, Canada., Haider HA; Epilepsy Center, Emory University School of Medicine, Atlanta, Georgia, USA., Hantus ST; Epilepsy Center, Cleveland Clinic, Neurological Institute, Cleveland, Ohio, USA., Hocker S; Mayo Clinic, Rochester, Minnesota, USA., Jongeling A; Department of Neurology, NYU Langone Medical Center, New York, New York, USA., Kalkach Aparicio M; Department of Neurology, University of Wisconsin, Madison, Wisconsin, USA., Kandula P; Department of Neurology, Weill Cornell Medicine, New York City, New York, USA., Kang P; Washington University School of Medicine, Saint Louis, Missouri, USA., Kazazian K; London Health Sciences Center, University Hospital, London, Ontario, Canada., Kellogg MA; Oregon Health & Science University, Portland, Oregon, USA., Kim M; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Lee JW; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Marcuse LV; Icahn School of Medicine at Mount Sinai, New York, New York, USA., McGraw CM; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Mohamed W; Wayne State University School of Medicine, Detroit, Michigan, USA., Orozco J; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Pimentel CM; Neurocritical Care, Emory University, Atlanta, Georgia, USA., Punia V; Epilepsy Center, Cleveland Clinic, Neurological Institute, Cleveland, Ohio, USA., Ramirez AM; Division of Neurocritical Care, Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio, USA., Steriade C; Department of Neurology, NYU Langone Medical Center, New York, New York, USA., Struck AF; Department of Neurology, University of Wisconsin, Madison, Wisconsin, USA., Taraschenko O; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA., Treister AK; Oregon Health & Science University, Portland, Oregon, USA., Wainwright MS; Divison of Pediatric Neurology, University of Washington, Seattle, Washington, USA., Yoo JY; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Zafar S; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA., Zhou DJ; Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA., Zutshi D; Wayne State University School of Medicine, Detroit, Michigan, USA., Gaspard N; Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Neurology, Hôpital Universitaire de Bruxelles-Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium., Hirsch LJ; Department of Neurology, Comprehensive Epilepsy Center, Yale University School of Medicine, New Haven, Connecticut, USA.
المصدر: Epilepsia [Epilepsia] 2024 Jun 05. Date of Electronic Publication: 2024 Jun 05.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Country of Publication: United States NLM ID: 2983306R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-1167 (Electronic) Linking ISSN: 00139580 NLM ISO Abbreviation: Epilepsia Subsets: MEDLINE
أسماء مطبوعة: Publication: Malden, MA : Blackwell Science
Original Publication: Copenhagen : Munskgaard
مستخلص: In response to the evolving treatment landscape for new-onset refractory status epilepticus (NORSE) and the publication of consensus recommendations in 2022, we conducted a comparative analysis of NORSE management over time. Seventy-seven patients were enrolled by 32 centers, from July 2016 to August 2023, in the NORSE/FIRES biorepository at Yale. Immunotherapy was administered to 88% of patients after a median of 3 days, with 52% receiving second-line immunotherapy after a median of 12 days (anakinra 29%, rituximab 25%, and tocilizumab 19%). There was an increase in the use of second-line immunotherapies (odds ratio [OR] = 1.4, 95% CI = 1.1-1.8) and ketogenic diet (OR = 1.8, 95% CI = 1.3-2.6) over time. Specifically, patients from 2022 to 2023 more frequently received second-line immunotherapy (69% vs 40%; OR = 3.3; 95% CI = 1.3-8.9)-particularly anakinra (50% vs 13%; OR = 6.5; 95% CI = 2.3-21.0), and the ketogenic diet (OR = 6.8; 95% CI = 2.5-20.1)-than those before 2022. Among the 27 patients who received anakinra and/or tocilizumab, earlier administration after status epilepticus onset correlated with a shorter duration of status epilepticus (ρ = .519, p = .005). Our findings indicate an evolution in NORSE management, emphasizing the increasing use of second-line immunotherapies and the ketogenic diet. Future research will clarify the impact of these treatments and their timing on patient outcomes.
(© 2024 International League Against Epilepsy.)
References: Hirsch LJ, Gaspard N, van Baalen A, Nabbout R, Demeret S, Loddenkemper T, et al. Proposed consensus definitions for new‐onset refractory status epilepticus (NORSE), febrile infection‐related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018;59(4):739–744.
Kramer U, Chi C‐S, Lin K‐L, Specchio N, Sahin M, Olson H, et al. Febrile infection‐related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52(11):1956–1965.
Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, et al. New‐onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–1613.
Hanin A, Cespedes J, Dorgham K, Pulluru Y, Gopaul M, Gorochov G, et al. Cytokines in new‐onset refractory status epilepticus predict outcomes. Ann Neurol. 2023;94(1):75–90.
Saitoh M, Kobayashi K, Ohmori I, Tanaka Y, Tanaka K, Inoue T, et al. Cytokine‐related and sodium channel polymorphism as candidate predisposing factors for childhood encephalopathy FIRES/AERRPS. J Neurol Sci. 2016;368:272–276.
Sakuma H, Tanuma N, Kuki I, Takahashi Y, Shiomi M, Hayashi M. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection‐related refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2015;86(7):820–822.
Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New‐onset refractory status epilepticus (NORSE)—the potential role for immunotherapy. Epilepsy Behav. 2015;47:17–23.
Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure. 2013;22(1):70–73.
Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including. febrile infection‐related epilepsy syndrome (FIRES): statements and supporting evidence. Epilepsia. 2022;63(11):2840–2864.
Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection‐related epilepsy syndrome (FIRES): summary and clinical tools. Epilepsia. 2022;63(11):2827–2839.
Hanin A, Muscal E, Hirsch LJ. Second‐line immunotherapy in new‐onset refractory status epilepticus (NORSE). Epilepsia. 2024;65(5):1203–1223.
Lai Y‐C, Muscal E, Wells E, Shukla N, Eschbach K, Hyeong Lee K, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020;7(12):2467–2474.
Jun J‐S, Lee S‐T, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84(6):940–945.
Costagliola G, Depietri G, Michev A, Riva A, Foiadelli T, Savasta S, et al. Targeting inflammatory mediators in epilepsy: a systematic review of its molecular basis and clinical applications. Front Neurol. 2022;13:741244.
Horino A, Kuki I, Inoue T, Nukui M, Okazaki S, Kawawaki H, et al. Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome. Ann Clin Transl Neurol. 2021;8(3):645–655.
Nabbout R, Mazzuca M, Hubert P, Peudennier S, Allaire C, Flurin V, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia. 2010;51(10):2033–2037.
Shrestha A, Wood EL, Berrios‐Siervo G, Stredny CM, Boyer K, Vega C, et al. Long‐term neuropsychological outcomes in children with febrile infection‐related epilepsy syndrome (FIRES) treated with anakinra. Front Neurol. 2023;14:1100551.
Moreno‐Brauer D, Häusler M, Kluger G, Hensler J, van Baalen A. Spectrum, evolution, and clinical relationship of magnetic resonance imaging in 31 children with febrile infection‐related epilepsy syndrome. Neuropediatrics. 2024;55(1):9–15.
معلومات مُعتمدة: Philippe Foundation; The Daniel Raymond Wong Neurology Research Fund; the NORSE/FIRES Research Fund at Yale; Paratonnerre Association; Swebilius Foundation; Servier Institute
فهرسة مساهمة: Keywords: age; etiology; immunotherapy; new‐onset refractory status epilepticus; outcome
تواريخ الأحداث: Date Created: 20240605 Latest Revision: 20240605
رمز التحديث: 20240606
DOI: 10.1111/epi.18014
PMID: 38837761
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1167
DOI:10.1111/epi.18014